Gut bacterial β-glucuronidase (GUS) plays a pivotal role in the metabolism and reactivation
of a vast of glucuronide conjugates of both endogenous and xenobiotic compounds in the …

Gut microbial β-glucuronidase (GUS) is a potential therapeutic target to reduce
gastrointestinal toxicity caused by irinotecan. In this study, the inhibitory effects of 17 natural …

Glucuronidation is a major metabolism process of detoxification for carcinogens, 4
(methylnitrosamino)1(3pyridy)1butanone (NNK) and 1, 2dimethylhydrazine (DMH), of …

Gut bacterial β-glucuronidase is regarded as an important molecular target for several
therapeutic applications. Inhibitors of β-glucuronidase can effectively alleviate the drug …

The direct inhibition of bacterial β-glucuronidase (βG) activity is expected to reduce the
reactivation of glucuronide-conjugated drugs in the intestine, thereby reducing drug toxicity …

Gut microbial β-glucuronidases have the ability to deconjugate glucuronides of some drugs,
thus have been considered as an important drug target to alleviate the drug metabolites …

The genes GLB1 and GALC encode GLB1 isoform 1 and galactocerebrosidase,
respectively, which exhibit β-galactosidase activity in human lysosomes. GLB1 isoform 1 has …

CPT-11 is a widely-used anti-cancer drug that is converted in vivo to its active metabolite,
SN-38. In the liver, enzymes detoxify SN-38 by coupling it to a glucuronidate moiety and this …

Microbial β-glucuronidases (GUSs) cause severe gut toxicities that limit the efficacy of
cancer drugs and other therapeutics. Selective inhibitors of bacterial GUS have been shown …

Bacterial β-glucuronidase in the intestine is involved in the conversion of 7-ethyl-10-
hydroxycamptochecin glucuronide (derived from irinotecan) to 7-ethyl-10 …